Aspira Women’s Health, Inc. Expands Leadership Team with Industry Veteran
New Team Addition Is a Thought Leader in Reimbursement and Diagnostics Aspira Women s Health Inc. Austin, Texas
AUSTIN, Texas, May 11, 2021 (GLOBE NEWSWIRE) Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the appointment of a new member to its leadership team, Greg Richard. Greg Richard has joined the company as the Head of Corporate Strategy, Reimbursement and Managed Care reporting to Valerie Palmieri, President and CEO. Aspira’s global mission is to transform women’s health, starting with ovarian cancer. This new appointment furthers the Company’s mission to provide women of all ages, stages and ethnicities access to the best solutions to detect their gynecologic cancer risk as well as benign detection solutions such as Endocheck, for endometriosis.
About Aspira Women’s Health Inc.
Aspira Women’s Health, Inc. (formerly known as Vermillion Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1
® and OVERA
® to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX
88 Biggest Movers From Friday Benzinga 2/1/2021
Gainers
Siebert Financial Corp. (NASDAQ: SIEB) shares climbed 121.6% to close at $8.22 on Friday on heavy volume.
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) climbed 70.8% to close at $4.15 after the company announced the acquisition of Quellis Biosciences.
GameStop Corp. (NYSE: GME) shares added 67.9% to close at $325.00 after Robinhood said it would allow some buying of the stocks on Friday after sparking outrage over discontinuing purchases of GME, AMC, and high stocks seeing social media interest. The company’s stock dropped over 44% on Thursday.
Novavax, Inc. (NASDAQ: NVAX) surged 64.9% to close at $220.94 after the company said Thursday that its COVID-19 vaccine candidate NVX-COV2373 showed 89.3% efficacy in Phase 3 trials conducted in the United Kingdom.
Yeti roars, SolarWinds deflates: The best and worst performing Austin stocks in 2020 bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.